Elisabetta Coppola
A5001029550- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Mathematical Biology Tumor Growth
- CAR-T cell therapy research
- Colorectal Cancer Surgical Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Bladder and Urothelial Cancer Treatments
- Pancreatic and Hepatic Oncology Research
- Urinary and Genital Oncology Studies
- COVID-19 and healthcare impacts
- Blood Pressure and Hypertension Studies
- Economic and Financial Impacts of Cancer
- Immunotherapy and Immune Responses
- Telemedicine and Telehealth Implementation
- Surgical site infection prevention
- Autoimmune and Inflammatory Disorders
- Cancer Mechanisms and Therapy
- Integrated Circuits and Semiconductor Failure Analysis
- Diverticular Disease and Complications
- Lung Cancer Diagnosis and Treatment
- Advancements in Semiconductor Devices and Circuit Design
- Anorectal Disease Treatments and Outcomes
- Lymphoma Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- PARP inhibition in cancer therapy
Fondazione IRCCS Istituto Nazionale dei Tumori
2024
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2022-2024
IRCCS Humanitas Research Hospital
2022
Humanitas University
2021-2022
University of Bologna
2021
Abstract Background This study compared patients undergoing colorectal cancer surgery in 20 hospitals of northern Italy 2019 versus 2020, order to evaluate whether COVID-19-related delays screening resulted more advanced cancers at diagnosis and worse clinical outcomes. Method was a retrospective multicentre cohort analysis March December 2020. Independent predictors disease stage (oncological stage, associated symptoms, T4 metastasis) outcome (surgical complications, palliative surgery,...
Abstract Background Stoma-reversal surgery is associated with high postoperative morbidity, including wound complications and surgical-site infections (SSIs). This study aims to assess whether the application of negative-pressure therapy (NPWT) can improve healing compared conventional dressing. Methods was a single-centre, superiority, open-label, parallel, individually randomized controlled trial. Patients undergoing stoma reversal were (1 : 1) receive NPWT or The primary endpoint rate...
Abstract Magnetic resonance imaging (MRI) is routinely used for preoperative tumor staging and to assess response therapy in rectal cancer patients. The aim of our study was evaluate the accuracy MRI based restaging after neoadjuvant chemoradiotherapy (CRT) predicting pathologic response. This multicenter cohort included adult patients with histologically confirmed locally advanced adenocarcinoma treated CRT followed by curative intent elective surgery between January 2014 December 2019 at...
To identify predictive factors of nivolumab sensitivity, peripheral blood NKs and regulatory T-cell (Treg) were evaluated in patients with metastatic renal cell carcinoma (mRCC) enrolled the REVOLUTION trial.
Cervical cancer (CC) is the second most commonly diagnosed and third leading cause of death among females. The options treatment for recurrent/advanced CC are limited patients experiencing recurrence after first line platinum-based chemotherapy have a poor prognosis. In this context, immune checkpoint inhibitors (ICI)s antagonizing PD-1 programmed death-ligand 1 (PD-L1) profoundly changed scenario outcomes in or subsequent lines both as monotherapies combination with other ICIs. Herein, we...
The axis CXCL12-CXCR4 is highly expressed in ovarian cancer where contributes to disease progression. Aim of the work was evaluate effect newly developed CXCR4 antagonist R54 on human cells aggressiveness. evaluated through proliferation, migration and signaling CXCL12-dependents. Epithelial mesenchymal transition (EMT) analyzed E-CADHERIN , N-CADHERIN VIMENTIN SNAIL1 ΒETA-CATENIN by qRT-PCR, immunofluorescence immunoblotting. inhibited proliferation CXCL12-induced. Moreover, CXCL12...
<p>Supplementary Figure S10. .632+ cross validation bootstrap ROC curves and the optimum T1 cut-off values of CD3<sup>+</sup> <sup>KIR2DL2/DL3+</sup>NKs to determine outcome REV patients</p>
<div>AbstractPurpose:<p>To identify predictive factors of nivolumab sensitivity, peripheral blood NKs and regulatory T-cell (Treg) were evaluated in patients with metastatic renal cell carcinoma (mRCC) enrolled the REVOLUTION trial.</p>Experimental Design:<p>Fifty-seven mRCCs being treated nivolumab, as at least second-line therapy, 62 healthy donors longitudinally (0–1–3–6–12 months) for Tregs, phenotype, function. Multivariable logistic regression was conducted to...
<p>Supplementary Figure S12. Correlation between pretreatment of <sup>PD-1+</sup>Tregs and <sup>Helios+</sup>Tregs in Responder Not-Responder patients.</p>
<p>Supplementary Figure S4. Pretreatment NKs co-expression of PD-1 and KIR2DL1or KIR2DL2/DL3 in mRCC-REV patients.</p>
<p>Supplementary Figure S6. Swimmer’s plot of nivolumab-treated mRCC patients.</p>
<p>Supplementary Figure S2. Correlation between age and pretreatment NKs Tregs immune subsets cells in mRCC-REV patients HDs.</p>
<p>Supplementary Figure S11. HLA class I in primary RCC from REV patients</p>
<p>Supplementary Figure S3. Pretreatment NKs and Tregs in mRCC-REV patients</p>
<p>Supplementary Figure S8. .632+ cross validation bootstrap ROC curves and the optimum pretreatment cut-off values of <sup>KIR2DL2/DL3+</sup>NKs <sup>Helios+</sup>Tregs to determine outcome REV patients</p>
<p>Supplementary Figure S13. T0-T1 values (after one month of nivolumab) between <sup>PD-1+</sup> Tregs and <sup>Helios+</sup>Tregs in Responder Not patients</p>
<p>Supplementary Figure S9. Association between the <sup>KIR2DL2/DL3+</sup>NKs/<sup>Helios+</sup>Tregs values and response to nivolumab treatment.</p>
<p>Supplementary Figure S7. Pretreatment NKs and Tregs subpopulations in mRCC-REV Long Responder (LR) patients vs Not-Responders (NR).</p>
<p>Supplementary Figure S5. Nivolumab did not significantly affect peripheral NKs and Tregs</p>
<p>Supplementary Figure S1. Gating strategy for identification of Tregs and NKs in peripheral blood.</p>
The primary goal of the Campania Oncology Network (ROC) was to reduce cancer delay and care fragmentation through establishment cancer-specific multidisciplinary oncologic groups (GOMs) diagnostic therapeutic assistance paths (PDTAs).Five centres ROC, with their own specific GOM, were selected. In our analysis, we have focused on four neoplasms: lung, colon, ovarian prostate cancers. median time for pre-GOM GOM Times calculated each tumour site. Univariate multivariate logistic regressions...